Role of Intravenous Levetiracetam in Acute Seizure Management of Children

Batool F. Kirmani, Edwin D. Crisp, Saima Kayani, Hasan Rajab

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Status epilepticus is defined as a seizure lasting beyond 30minutes. Children with intractable epilepsy undergo frequent hospital admissions secondary to status epilepticus or because of acute exacerbation of seizures. Intravenous levetiracetam became available in August 2006 for use in patients aged above 16 years. There are insufficient data about the efficacy and safety of intravenous levetiracetam in children. We retrospectively analyzed data from children treated with intravenous levetiracetam for status epilepticus and acute exacerbation of seizures. We acquired data from our institution's electronic medical records concerning patients with status epilepticus and acute exacerbation of seizures who received intravenous levetiracetam. Thirty-two patients (age range, 2 months to 18 years) had received a levetiracetam load of 25-50 mg/kg for status epilepticus. There were 17 (53.1%) males and 15 (46.8%) females. Response to intravenous levetiracetam in all patients was favorable. Status epilepticus ceased clinically and electrographically. Eighteen patients (56.5%) received intravenous levetiracetam after receiving fosphenytoin and Ativan with no response. No serious side effects were evident. Fifteen patients (46.8%) were discharged on levetiracetam monotherapy, and 9 (28.1%) received levetiracetam as adjunctive therapy after discharge from the hospital. Intravenous levetiracetam can be used adjunctively or as monotherapy in children with status epilepticus and acute exacerbation of seizures.

Original languageEnglish (US)
Pages (from-to)37-39
Number of pages3
JournalPediatric Neurology
Volume41
Issue number1
DOIs
StatePublished - Jul 1 2009

Fingerprint

etiracetam
Seizures
Status Epilepticus
Lorazepam

ASJC Scopus subject areas

  • Clinical Neurology
  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Neurology

Cite this

Role of Intravenous Levetiracetam in Acute Seizure Management of Children. / Kirmani, Batool F.; Crisp, Edwin D.; Kayani, Saima; Rajab, Hasan.

In: Pediatric Neurology, Vol. 41, No. 1, 01.07.2009, p. 37-39.

Research output: Contribution to journalArticle

Kirmani, Batool F. ; Crisp, Edwin D. ; Kayani, Saima ; Rajab, Hasan. / Role of Intravenous Levetiracetam in Acute Seizure Management of Children. In: Pediatric Neurology. 2009 ; Vol. 41, No. 1. pp. 37-39.
@article{8d6864e7409a4499bdcb605102e97a57,
title = "Role of Intravenous Levetiracetam in Acute Seizure Management of Children",
abstract = "Status epilepticus is defined as a seizure lasting beyond 30minutes. Children with intractable epilepsy undergo frequent hospital admissions secondary to status epilepticus or because of acute exacerbation of seizures. Intravenous levetiracetam became available in August 2006 for use in patients aged above 16 years. There are insufficient data about the efficacy and safety of intravenous levetiracetam in children. We retrospectively analyzed data from children treated with intravenous levetiracetam for status epilepticus and acute exacerbation of seizures. We acquired data from our institution's electronic medical records concerning patients with status epilepticus and acute exacerbation of seizures who received intravenous levetiracetam. Thirty-two patients (age range, 2 months to 18 years) had received a levetiracetam load of 25-50 mg/kg for status epilepticus. There were 17 (53.1{\%}) males and 15 (46.8{\%}) females. Response to intravenous levetiracetam in all patients was favorable. Status epilepticus ceased clinically and electrographically. Eighteen patients (56.5{\%}) received intravenous levetiracetam after receiving fosphenytoin and Ativan with no response. No serious side effects were evident. Fifteen patients (46.8{\%}) were discharged on levetiracetam monotherapy, and 9 (28.1{\%}) received levetiracetam as adjunctive therapy after discharge from the hospital. Intravenous levetiracetam can be used adjunctively or as monotherapy in children with status epilepticus and acute exacerbation of seizures.",
author = "Kirmani, {Batool F.} and Crisp, {Edwin D.} and Saima Kayani and Hasan Rajab",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.pediatrneurol.2009.02.016",
language = "English (US)",
volume = "41",
pages = "37--39",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Role of Intravenous Levetiracetam in Acute Seizure Management of Children

AU - Kirmani, Batool F.

AU - Crisp, Edwin D.

AU - Kayani, Saima

AU - Rajab, Hasan

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Status epilepticus is defined as a seizure lasting beyond 30minutes. Children with intractable epilepsy undergo frequent hospital admissions secondary to status epilepticus or because of acute exacerbation of seizures. Intravenous levetiracetam became available in August 2006 for use in patients aged above 16 years. There are insufficient data about the efficacy and safety of intravenous levetiracetam in children. We retrospectively analyzed data from children treated with intravenous levetiracetam for status epilepticus and acute exacerbation of seizures. We acquired data from our institution's electronic medical records concerning patients with status epilepticus and acute exacerbation of seizures who received intravenous levetiracetam. Thirty-two patients (age range, 2 months to 18 years) had received a levetiracetam load of 25-50 mg/kg for status epilepticus. There were 17 (53.1%) males and 15 (46.8%) females. Response to intravenous levetiracetam in all patients was favorable. Status epilepticus ceased clinically and electrographically. Eighteen patients (56.5%) received intravenous levetiracetam after receiving fosphenytoin and Ativan with no response. No serious side effects were evident. Fifteen patients (46.8%) were discharged on levetiracetam monotherapy, and 9 (28.1%) received levetiracetam as adjunctive therapy after discharge from the hospital. Intravenous levetiracetam can be used adjunctively or as monotherapy in children with status epilepticus and acute exacerbation of seizures.

AB - Status epilepticus is defined as a seizure lasting beyond 30minutes. Children with intractable epilepsy undergo frequent hospital admissions secondary to status epilepticus or because of acute exacerbation of seizures. Intravenous levetiracetam became available in August 2006 for use in patients aged above 16 years. There are insufficient data about the efficacy and safety of intravenous levetiracetam in children. We retrospectively analyzed data from children treated with intravenous levetiracetam for status epilepticus and acute exacerbation of seizures. We acquired data from our institution's electronic medical records concerning patients with status epilepticus and acute exacerbation of seizures who received intravenous levetiracetam. Thirty-two patients (age range, 2 months to 18 years) had received a levetiracetam load of 25-50 mg/kg for status epilepticus. There were 17 (53.1%) males and 15 (46.8%) females. Response to intravenous levetiracetam in all patients was favorable. Status epilepticus ceased clinically and electrographically. Eighteen patients (56.5%) received intravenous levetiracetam after receiving fosphenytoin and Ativan with no response. No serious side effects were evident. Fifteen patients (46.8%) were discharged on levetiracetam monotherapy, and 9 (28.1%) received levetiracetam as adjunctive therapy after discharge from the hospital. Intravenous levetiracetam can be used adjunctively or as monotherapy in children with status epilepticus and acute exacerbation of seizures.

UR - http://www.scopus.com/inward/record.url?scp=66349133603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66349133603&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2009.02.016

DO - 10.1016/j.pediatrneurol.2009.02.016

M3 - Article

C2 - 19520272

AN - SCOPUS:66349133603

VL - 41

SP - 37

EP - 39

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

IS - 1

ER -